" class="no-js "lang="en-US"> Syndax Pharmaceuticals - Medtech Alert
Monday, September 22, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Syndax Pharmaceuticals | Pharmtech Focus

Syndax Pharmaceuticals

About Syndax Pharmaceuticals

Syndax Pharmaceuticals

Syndax Pharmaceuticals is a Biotechnology company located at 35 Gatehouse Dr., Building D, Floor 3, Waltham, MA 02451.

Related Story

Diseases

 Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients | MTA

Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients

March 16 2023

Syndax Pharmaceuticals, today announced that data from the Phase 1 portion of the ongoing Phase […]

Clinical Trials

 Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia | PTF

Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia

December 6 2022

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced […]

Appointments

 Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer | PTF

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

December 2 2022

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, has announced […]

Diseases

 Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia | Pharmtech Focus

Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia

December 22 2021

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing […]